

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJRK1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 AUG 06 CAS REGISTRY enhanced with new experimental property tags
NEWS 3 AUG 06 FSTA enhanced with new thesaurus edition
NEWS 4 AUG 13 CA/CAPLUS enhanced with additional kind codes for granted
patents
NEWS 5 AUG 20 CA/CAPLUS enhanced with CAS indexing in pre-1907 records
NEWS 6 AUG 27 Full-text patent databases enhanced with predefined
patent family display formats from INPADOCDB
NEWS 7 AUG 27 USPATOLD now available on STN
NEWS 8 AUG 28 CAS REGISTRY enhanced with additional experimental
spectral property data
NEWS 9 SEP 07 STN AnaVist, Version 2.0, now available with Derwent
World Patents Index
NEWS 10 SEP 13 FORIS renamed to SOFIS
NEWS 11 SEP 13 INPADOCDB enhanced with monthly SDI frequency
NEWS 12 SEP 17 CA/CAPLUS enhanced with printed CA page images from
1967-1998
NEWS 13 SEP 17 CAPLUS coverage extended to include traditional medicine
patents
NEWS 14 SEP 24 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 15 OCT 02 CA/CAPLUS enhanced with pre-1907 records from Chemisches
Zentralblatt
NEWS 16 OCT 19 BEILSTEIN updated with new compounds
NEWS 17 NOV 15 Derwent Indian patent publication number format enhanced
NEWS 18 NOV 19 WPIX enhanced with XML display format
NEWS 19 NOV 30 ICSD reloaded with enhancements
NEWS 20 DEC 04 LINPADOCDB now available on STN
NEWS 21 DEC 14 BEILSTEIN pricing structure to change
NEWS 22 DEC 17 USPATOLD added to additional database clusters
NEWS 23 DEC 17 IMSDRUGCONF removed from database clusters and STN
NEWS 24 DEC 17 DGENE now includes more than 10 million sequences
NEWS 25 DEC 17 TOXCENTER enhanced with 2008 MeSH vocabulary in
MEDLINE segment
NEWS 26 DEC 17 MEDLINE and LEMEDLINE updated with 2008 MeSH vocabulary
NEWS 27 DEC 17 CA/CAPLUS enhanced with new custom IPC display formats
NEWS 28 DEC 17 STN Viewer enhanced with full-text patent content
from USPATOLD
NEWS 29 JAN 02 STN pricing information for 2008 now available
NEWS 30 JAN 16 CAS patent coverage enhanced to include exemplified
prophetic substances
NEWS 31 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new

custom IPC display formats
 NEWS 32 JAN 28 MARPAT searching enhanced
 NEWS 33 JAN 28 USGENE now provides USPTO sequence data within 3 days
 of publication
 NEWS 34 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment
 NEWS 35 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements
 NEWS 36 FEB 08 STN Express, Version 8.3, now available

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
 AND CURRENT DISCOVER FILE IS DATED 24 JANUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN Welcome Banner and News Items
 NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
 specific topic.

All use of STN is subject to the provisions of the STN Customer
 agreement. Please note that this agreement limits use to scientific
 research. Use for software development or design or implementation
 of commercial gateways or other similar uses is prohibited and may
 result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 08:51:09 ON 19 FEB 2008

=> file reg

| | | |
|----------------------|------------|---------|
| COST IN U.S. DOLLARS | SINCE FILE | TOTAL |
| | ENTRY | SESSION |
| FULL ESTIMATED COST | 0.21 | 0.21 |

FILE 'REGISTRY' ENTERED AT 08:51:21 ON 19 FEB 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 18 FEB 2008 HIGHEST RN 1004360-55-7
 DICTIONARY FILE UPDATES: 18 FEB 2008 HIGHEST RN 1004360-55-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.


Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10524162\Struc 1.str



```

chain nodes :
1 20 21 22 23 34 35
ring nodes :
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 24 25 26 27 28
29 30 31 32 33
chain bonds :
1-2 1-3 1-4 11-21 18-20 20-22 21-23 22-24 23-25 29-35 33-34
ring bonds :
2-10 2-14 3-15 3-19 4-5 4-9 5-6 6-7 7-8 8-9 10-11 11-12 12-13 13-14
15-16 16-17 17-18 18-19 24-26 24-29 25-30 25-33 26-27 27-28 28-29 30-31
31-32 32-33
exact/norm bonds :
20-22 21-23 22-24 23-25 24-26 24-29 25-30 25-33 26-27 27-28 28-29 30-31
31-32 32-33
exact bonds :
1-2 1-3 1-4 11-21 18-20 29-35 33-34
normalized bonds :
2-10 2-14 3-15 3-19 4-5 4-9 5-6 6-7 7-8 8-9 10-11 11-12 12-13 13-14
15-16 16-17 17-18 18-19

```

Match level :

1:CLASS 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:CLASS 35:CLASS

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> l1

SAMPLE SEARCH INITIATED 08:51:48 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 6 TO ITERATE

100.0% PROCESSED 6 ITERATIONS 6 ANSWERS
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 6 TO 266
 PROJECTED ANSWERS: 6 TO 266

L2 6 SEA SSS SAM L1

=> l1 full

FULL SEARCH INITIATED 08:51:51 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 114 TO ITERATE

100.0% PROCESSED 114 ITERATIONS 105 ANSWERS
 SEARCH TIME: 00.00.01

L3 105 SEA SSS FUL L1

=> file caplus

| | | |
|----------------------|------------|---------|
| COST IN U.S. DOLLARS | SINCE FILE | TOTAL |
| | ENTRY | SESSION |
| FULL ESTIMATED COST | 178.36 | 178.57 |

FILE 'CAPLUS' ENTERED AT 08:52:01 ON 19 FEB 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December

26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Feb 2008 VOL 148 ISS 8
FILE LAST UPDATED: 18 Feb 2008 (20080218/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> 13

L4 10 L3

=> d ibib abs hitstr 1-10

L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:647626 CAPLUS

DOCUMENT NUMBER: 145:224185

TITLE: Cold virus fusion or stopping fusion cold - inhibitors of the human respiratory syncytial virus F protein
AUTHOR(S): Del Vecchio, Alfred M.; Sarisky, Robert T.
CORPORATE SOURCE: Infectious Diseases Research, Centocor, Inc., Radnor, PA, 19087, USA

SOURCE: Recent Patents on Anti-Infective Drug Discovery (2006), 1(2), 247-254
CODEN: RPADCX; ISSN: 1574-891X

PUBLISHER: Bentham Science Publishers Ltd.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English


AB A review. Human respiratory syncytial virus (HRSV) is a major respiratory viral pathogen causing moderate to severe upper and lower respiratory tract infections in all ages and across a wide range of patient populations. There are no currently approved vaccines and although a number of candidates are in various stages of development, the challenges are quite substantial. Presently, only a single agent is approved for HRSV prophylaxis, and therapeutic treatment options are severely limited and ineffective, particularly in the infant population. Antibody prophylaxis is restricted to use in populations at high-risk for hospitalization (infants under 35 wk gestational age, infants with chronic lung disease, and infants with congenital heart disease). Aerosol administration of the guanosine analog ribavirin has been approved for the treatment of severe HRSV LRTI in both children and mech. ventilated patients; however, there is still debate over its overall benefit and the risks associated with its use. Current therapy for those hospitalized due to HRSV is supportive. As such, there is great medical need for the development of agents to prevent and treat HRSV infections in all populations. Interestingly, many of the discovered agents against HRSV, both neutralizing antibodies and small mol. inhibitors, target the viral fusion (F) glycoprotein. In particular, three distinct chemical classes as exemplified by JNJ-2408068, VP-14637, and BMS-433771, which appear to block conformational intermediates of the viral fusion protein are reviewed.

IT 235106-62-4, VP-14637

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(cold virus fusion or stopping fusion cold - inhibitors of human
respiratory syncytial virus F protein)

RN 235106-62-4 CAPLUS

CN Phenol, 2,2'-[(4-hydroxyphenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 78 THERE ARE 78 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1028388 CAPLUS

DOCUMENT NUMBER: 143:379155

TITLE: Antiviral efficacy of VP14637 against respiratory syncytial virus in vitro and in cotton rats following delivery by small droplet aerosol

AUTHOR(S): Wyde, Philip R.; Laquerre, Sylvie; Chetty, Srikrishna N.; Gilbert, Brian E.; Nitz, Theodore J.; Pevear, Daniel C.

CORPORATE SOURCE: Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, 77030, USA

SOURCE: Antiviral Research (2005), 68(1), 18-26

CODEN: ARSRDR; ISSN: 0166-3542

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB VP14637, the lead compound in a series of substituted bis-tetrazole-benzhydrylphenols developed by ViroPharma Incorporated, was evaluated for antiviral efficacy against respiratory syncytial virus (RSV) in vitro in cell culture and in vivo in cotton rats. A selective index of > 3000 (≥ 2000 times greater than that observed for ribavirin) was determined in the in vitro studies for this compound against both RSV A and B subtypes. In cotton rats, animals given as little as 126 µg drug/kg by small droplet aerosol in divided doses starting 1 day after exptl. virus infection with either a RSV A or B subtype consistently had significantly lower mean pulmonary RSV titers and reduced histopathol. findings than mock-treated animals or cotton rats given placebo (vehicle-treated animals). No cotton rat treated with aerosols of VP14637 during these studies manifested any evident untoward responses. Thus, VP14637 exhibited good selective antiviral efficacy both in vitro and in vivo.


IT 235106-62-4, VP14637

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological

activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiviral efficacy of VP14637 against respiratory syncytial virus in
vitro and in cotton rats following delivery by small droplet aerosol)

RN 235106-62-4 CAPLUS

CN Phenol, 2,2'-[4-(4-hydroxyphenyl)methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:494325 CAPLUS

DOCUMENT NUMBER: 143:90328

TITLE: Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms

AUTHOR(S): Douglas, Janet L.; Panis, Marites L.; Ho, Edmund; Lin, Kuei-Ying; Krawczyk, Steve H.; Grant, Deborah M.; Cai, Ruby; Swaminathan, Swami; Chen, Xiaowu; Cihlar, Tomas

CORPORATE SOURCE: Gilead, Foster City, CA, 94404, USA

SOURCE: Antimicrobial Agents and Chemotherapy (2005), 49(6), 2460-2466

CODEN: AMACQ; ISSN: 0066-4804

PUBLISHER: American Society for Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Here we present data on the mechanism of action of VP-14637 and JNJ-2408068 (formerly R-170591), two small-mol. inhibitors of respiratory syncytial virus (RSV). Both inhibitors exhibited potent antiviral activity with 50% effective concns. (EC50s) of 1.4 and 2.1 nM, resp. A similar inhibitory effect was observed in a RSV-mediated cell fusion assay (EC50 = 5.4 and 0.9 nM, resp.). Several drug-resistant RSV variants were selected in vitro in the presence of each compound. All selected viruses exhibited significant cross-resistance to both inhibitors and contained various single amino acid substitutions in two distinct regions of the viral F protein, the heptad repeat 2 (HR2; mutations D486N, E487D, and F488Y), and the intervening domain between HR1 and HR2 (mutation K399I and T400A). Studies using [3H]VP-14637 revealed a specific binding of the compound to RSV-infected cells that was efficiently inhibited by JNJ-2408068 (50% inhibitory concentration = 2.9 nM) but not by the HR2-derived peptide T-118.

Further anal. using a transient T7 vaccinia expression system indicated that RSV F protein is sufficient for this interaction. F proteins containing

either the VP-14637 or JNJ-2408068 resistance mutations exhibited greatly reduced binding of [3H]VP-14637. Mol. modeling anal. suggests that both mols. may bind into a small hydrophobic cavity in the inner core of F protein, interacting simultaneously with both the HR1 and HR2 domains. Altogether, these data indicate that VP-14637 and JNJ-2408068 interfere with RSV fusion through a mechanism involving a similar interaction with the F protein.


IT 235106-62-4, VP-14637

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(small mols. VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms by binding into a small hydrophobic cavity in the inner core of F protein, interacting simultaneously with both the HR1 and HR2 domains)

RN 235106-62-4 CAPLUS

CN Phenol, 2,2'-[(4-hydroxyphenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:142914 CAPLUS

DOCUMENT NUMBER: 140:181453

TITLE: Preparation of 2,2'-(phenylmethylene)bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]phenol compounds, pharmaceutical compositions, and methods for treating or preventing pneumovirus infection and associated diseases

INVENTOR(S): Rys, David J.; Nitz, Theodore J.; Gaboury, Janet A.; Burns, Christopher J.; Pevear, Daniel C.; Lessen, Thomas A.; Herberitz, Torsten

PATENT ASSIGNEE(S): Viropharma Incorporated, USA

SOURCE: PCT Int. Appl., 95 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------|----------|
| ----- | --- | ----- | ----- | ----- |
| WO 2004014317 | A2 | 20040219 | WO 2003-US25166 | 20030811 |

WO 2004014317 A3 20040415

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2495245 A1 20040219 CA 2003-2495245 20030811

AU 2003258177 A1 20040225 AU 2003-258177 20030811

EP 1539691 A2 20050615 EP 2003-785209 20030811

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK


US 2005288345 A1 20051229 US 2005-524313 20050715

PRIORITY APPLN. INFO.: US 2002-402402P P 20020809

WO 2003-US25166 W 20030811

OTHER SOURCE(S): MARPAT 140:181453

GI



I


AB The title compds. (I; R1 = alkoxy, alkoxyalkyl, halogen, nitro, carboxy, carboxyalkyl, carbalkoxy, carbalkoxyalkyl, carboxamide, carboxamidoalkyl, alkyl, cycloalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, sulfonamide, amidino, cyano, amino, amido, alkylamino, dialkylamino, alkylaminoalkyl, alkoxy monosubstituted with a substituent selected from the group consisting of carboxy, amino, alkylamino and dialkylamino) and pharmaceutically acceptable salts are prepared. Pharmaceutical compns. and methods are also provided for the prophylaxis and treatment of infections caused by viruses of the Pneumovirinae subfamily of Paramyxoviridae and diseases associated with such infections. The compds. I showed IC50 of 0.1 nM to 1 µM in an cell culture assay for inhibition of Pneumovirus replication using HEp2 cells.

IT 660408-49-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 2,2'-(phenylmethylene)bis[[(methyl-1H-tetrazolyl)imino]methyl]phenol] compds. for treating or preventing pneumovirus infection and associated diseases)

RN 660408-49-1 CAPLUS

CN Phenol, 2,2'-[[3-(propylphenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




IT 660408-51-5P 660408-53-7P 660408-54-8P
660408-56-0P 660408-58-2P 660408-60-6P
660408-62-8P 660408-64-0P 660408-66-2P
660408-68-4P 660408-70-8P 660408-72-0P
660408-74-2P 660408-76-4P 660408-78-6P
660408-80-0P 660408-82-2P 660408-84-4P
660408-86-6P 660408-87-7P 660408-89-9P
660408-91-3P 660408-93-5P 660408-95-7P
660408-97-9P 660408-99-1P 660409-01-8P
660409-03-0P 660409-05-2P 660409-07-4P
660409-09-6P 660409-11-0P 660409-12-1P
660409-15-4P 660409-17-6P 660409-19-8P
660409-21-2P 660409-22-3P 660409-23-4P
660409-24-5P 660409-25-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2,2'-(phenylmethylene)bis[[(methyl-1H-tetrazolyl)imino]methyl]phenol] compds. for treating or preventing pneumovirus infection and associated diseases)


RN 660408-51-5 CAPLUS

CN Phenol, 2,2'-[[3-(dimethylamino)phenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 660408-53-7 CAPLUS

CN Phenol, 2,2'-[[3-(1-methylethyl)phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)




RN 660408-54-8 CAPLUS

CN Phenol, 2,2'-[[3-methylphenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)




RN 660408-56-0 CAPLUS


CN Phenol, 2,2'-[[3-methoxyphenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)




RN 660408-58-2 CAPLUS
CN Phenol, 2,2'-[(3-ethoxyphenyl)methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)



RN 660408-60-6 CAPLUS
CN Phenol, 2,2'-[(3-ethoxyphenyl)methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)




RN 660408-62-8 CAPLUS
CN Phenol, 2,2'-[(3-bromophenyl)methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)




RN 660408-64-0 CAPLUS

CN Phenol, 2,2'-[[3-(2-ethylbutyl)phenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 660408-66-2 CAPLUS

CN Phenol, 2,2'-[[3-(3-cyclohexylphenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 660408-68-4 CAPLUS

CN Phenol, 2,2'-[[3-(3-butylphenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 660408-70-8 CAPLUS

CN Phenol, 2,2'-[(3-fluorophenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 660408-72-0 CAPLUS

CN Phenol, 2,2'-[(3-pentylphenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 660408-74-2 CAPLUS

CN Phenol, 2,2'-[[3-(1-methylpropyl)phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 660408-76-4 CAPLUS

CN Phenol, 2,2'-[[3-(2-methylpropyl)phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 660408-78-6 CAPLUS

CN Phenol, 2,2'-[[3-(2-methoxyethyl)phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 660408-80-0 CAPLUS

CN Phenol, 2,2'-[[3-(2-ethylphenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 660408-82-2 CAPLUS

CN Phenol, 2,2'-[[3-[(ethyl(1-methylethyl)amino)phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (9CI) (CA INDEX NAME)




RN 660408-84-4 CAPLUS

CN Phenol, 2,2'-[[3-(ethylpropylamino)phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 660408-86-6 CAPLUS

CN Phenol, 2,2'-[[3-(diethylamino)phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 660408-87-7 CAPLUS

CN Phenol, 2,2'-[[3-(butylethylamino)phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)




RN 660408-89-9 CAPLUS

CN Phenol, 2,2'-[[3-(methylethylamino)phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (9CI) (CA INDEX NAME)




RN 660408-91-3 CAPLUS

CN Benzenesulfonamide, 3-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]phenyl]methyl]-N,N-diethyl- (CA INDEX NAME)




RN 660408-93-5 CAPLUS

CN Phenol, 2,2'-[[3-[2-(dimethylamino)ethoxy]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 660408-95-7 CAPLUS

CN Propanamide, N-[3-[bis[2-hydroxy-5-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]phenyl]methyl]phenyl]-2,2-dimethyl- (CA INDEX NAME)




RN 660408-97-9 CAPLUS

CN 1-Butanesulfonamide, N-[3-[bis[2-hydroxy-5-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]phenyl]methyl]phenyl]- (CA INDEX NAME)




RN 660408-99-1 CAPLUS

CN Phenol, 2,2'-[3-(3-nitrophenyl)methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)




RN 660409-01-8 CAPLUS

CN Phenol, 2,2'-[[3-(methylthio)phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)




RN 660409-03-0 CAPLUS

CN Phenol, 2,2'-[[3-(methylsulfinyl)phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)




RN 660409-05-2 CAPLUS

CN Phenol, 2,2'-[[3-(methylsulfonyl)phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)




RN 660409-07-4 CAPLUS

CN Benzenesulfonamide, 3-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]phenyl]methyl]-N,N-dimethyl- (CA INDEX NAME)




RN 660409-09-6 CAPLUS

CN Phenol, 2,2'-[[3-(propylamino)phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (9CI) (CA INDEX NAME)




RN 660409-11-0 CAPLUS

CN Phenol, 2,2'-[3-[3-(diethylamino)propoxy]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 660409-12-1 CAPLUS

CN Acetamide, N-[3-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]phenyl]methyl]phenyl]- (CA INDEX NAME)




RN 660409-15-4 CAPLUS


CN Acetamide, N-[3-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]phenyl]methyl]phenyl]-N-propyl- (CA INDEX NAME)




RN 660409-17-6 CAPLUS
 CN Acetamide, N-[3-[bis[2-hydroxy-5-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]phenyl]methyl]phenyl]-N-(1-methylethyl)- (CA INDEX NAME)




RN 660409-19-8 CAPLUS
 CN Butanamide, N-[3-[bis[2-hydroxy-5-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]phenyl]methyl]phenyl]-3-methyl-N-propyl- (CA INDEX NAME)




RN 660409-21-2 CAPLUS
 CN Butanamide, N-[3-[bis[2-hydroxy-5-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]phenyl]methyl]phenyl]-3-methyl-N-(1-methylethyl)- (CA INDEX NAME)




RN 660409-22-3 CAPLUS
 CN Butanamide, N-[3-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]phenyl]methyl]phenyl]-N,3-dimethyl- (CA INDEX NAME)



RN 660409-23-4 CAPLUS
 CN Acetamide, N-[3-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]phenyl]methyl]phenyl]-N-ethyl- (CA INDEX NAME)




RN 660409-24-5 CAPLUS
 CN 1-Propanesulfonamide, N-[3-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]phenyl]methyl]phenyl]- (CA INDEX NAME)



RN 660409-25-6 CAPLUS

CN Phenol, 2,2'-[[3-[[methyl(1-methylethyl)amino]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (9CI) (CA INDEX NAME)




IT 660409-26-7P 660409-27-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prodrug; preparation of 2,2'-(phenylmethylene)bis[[[(methyl-1H-tetrazolyl)imino]methyl]phenol] compds. for treating or preventing pneumovirus infection and associated diseases)


RN 660409-26-7 CAPLUS

CN Phenol, 2,2'-[[3-propylphenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]-, dipropionate (ester) (9CI) (CA INDEX NAME)



RN 660409-27-8 CAPLUS

CN Phenol, 2,2'-[(3-propylphenyl)methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]-, diacetate (ester) (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:142913 CAPLUS

DOCUMENT NUMBER: 140:181452

TITLE: Preparation of triaryl bistetrazole derivatives for treating or preventing pneumovirus infection and associated diseases

INVENTOR(S): Nitz, Theodore J.; Gaboury, Janet A.; Burns, Christopher J.; Laquerre, Sylvie; Pevear, Daniel C.; Lessen, Thomas A.; Rys, David J.

PATENT ASSIGNEE(S): Viropharma Incorporated, USA

SOURCE: PCT Int. Appl., 130 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|--|----------|-----------------|------------|
| WO 2004014316 | A2 | 20040219 | WO 2003-US25165 | 20030811 |
| WO 2004014316 | A3 | 20040617 | | |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| CA 2495266 | A1 | 20040219 | CA 2003-2495266 | 20030811 |
| AU 2003258176 | A1 | 20040225 | AU 2003-258176 | 20030811 |
| EP 1545513 | A2 | 20050629 | EP 2003-785208 | 20030811 |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | |
| US 2005288344 | A1 | 20051229 | US 2005-524162 | 20050617 |
| PRIORITY APPLN. INFO.: | | | US 2002-402450P | P 20020809 |
| | | | WO 2003-US25165 | W 20030811 |
| OTHER SOURCE(S): | MARPAT 140:181452 | | | |
| GI | | | | |



AB The title compound I [R = alkyl, substituted amino, substituted SO₂NH₂, hydroxyalkyl, hydroxyalkoxy, polyhydroxyalkyl, alkoxyalkoxy, polyfluoroalkyl, dialkylaminoalkyl, heterocyclyl, etc.] were prepared for treating or preventing pneumovirus infection and associated diseases. Thus, reaction of 2,2'-[[3-[(2,2,2-trifluoroethyl)phenyl]methylene]bis(4-formyl)phenol (preparation given) with 1-amino-5-methyltetrazole yielded compound I (R = CH₂CF₃). The prepared compds. were assayed for the inhibition of the replication of several pneumoviruses with IC₅₀ range from 0.1 nM to 1 μM.

IT 658688-35-8P 658688-36-9P 658688-37-0P


658688-38-1P 658688-39-2P 658688-40-5P
 658688-41-6P 658688-42-7P 658688-43-8P
 658688-44-9P 658688-45-0P 658688-46-1P
 658688-47-2P 658688-48-3P 658688-49-4P
 658688-50-7P 658688-51-8P 658688-52-9P
 658688-53-0P 658688-54-1P 658688-55-2P
 658688-56-3P 658688-57-4P 658688-58-5P
 658688-59-6P 658688-60-9P 658688-61-0P
 658688-62-1P 658688-63-2P 658688-64-3P
 658688-65-4P 658688-66-5P 658688-67-6P
 658688-68-7P 658688-69-8P 658688-70-1P
 658688-71-2P 658688-72-3P 658688-73-4P
 658688-74-5P 658688-75-6P 658688-76-7P
 658688-77-8P 658688-78-9P 658688-79-0P
 658688-80-3P 658688-81-4P 658688-82-5P
 658688-83-6P 658688-84-7P 658688-85-8P
 658688-86-9P 658688-87-0P 658688-88-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of triaryl bistetrazole derivs. for treating or preventing
 pneumovirus infection and associated diseases)


RN 658688-35-8 CAPLUS

CN Phenol, 2,2'-[[3-(2,2,2-trifluoroethyl)phenyl)methylene]bis[4-[(5-methyl-
 1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 658688-36-9 CAPLUS

CN Benzeneethanol, 3-[bis[2-hydroxy-5-[(5-methyl-1H-tetrazol-1-
 yl)imino]methyl]phenyl)methyl]-, α -acetate (9CI) (CA INDEX NAME)




RN 658688-37-0 CAPLUS

CN Benzeneethanol, 3-[bis[2-hydroxy-5-[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]phenyl]methyl]- (CA INDEX NAME)




RN 658688-38-1 CAPLUS

CN Phenol, 2,2'-[[3-(4-morpholinyl)phenyl]methylene]bis[4-[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 658688-39-2 CAPLUS

CN Phenol, 2,2'-[[3-(1-piperidiny)phenyl]methylene]bis[4-[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 658688-40-5 CAPLUS

CN Benzenesulfonamide, 3-[bis[2-hydroxy-5-[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]phenyl]methyl]-N,N-bis(2-methoxyethyl)- (CA INDEX NAME)




RN 658688-41-6 CAPLUS

CN Benzenesulfonamide, 3-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]phenyl]methyl-N-(2-hydroxyethyl)-N-methyl- (CA INDEX NAME)




RN 658688-42-7 CAPLUS

CN Benzenepropanol, 3-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]phenyl]methyl-N-(2-hydroxyethyl)-N-methyl- (CA INDEX NAME)




RN 658688-43-8 CAPLUS

CN Morpholine, 4-[[3-[bis[2-hydroxy-5-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]phenyl]methyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 658688-44-9 CAPLUS

CN Phenol, 2,2'-[[3-(2-methoxyethoxy)phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)



RN 658688-45-0 CAPLUS


CN Phenol, 2,2'-[[3-[bis(phenylmethyl)amino]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (9CI) (CA INDEX NAME)



RN 658688-46-1 CAPLUS


CN Phenol, 2,2'-[[3-[2-(acetyloxy)ethoxy]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (9CI) (CA INDEX NAME)

1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 658688-47-2 CAPLUS

CN Benzenesulfonamide, N-[2-(acetyloxy)ethyl]-3-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)




RN 658688-48-3 CAPLUS

CN Phenol, 2,2'-[[3-(2-hydroxyethoxy)phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 658688-49-4 CAPLUS


CN Acetamide, N-[3-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]phenyl]methyl]phenyl]-2-hydroxy-N-(1-methylethyl)- (CA INDEX NAME)



RN 658688-50-7 CAPLUS
 CN Acetamide, 2-(acetyloxy)-N-[3-bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]phenyl]methyl]phenyl]-N-propyl- (CA INDEX NAME)




RN 658688-51-8 CAPLUS
 CN Phenol, 2,2'-[[3-[(4-methyl-1-piperazinyl)methyl]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)



RN 658688-52-9 CAPLUS
 CN Phenol, 2,2'-[[3-[(4-methyl-1-piperazinyl)methyl]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]-, mono(4-methylbenzenesulfonate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 658688-51-8
CMF C31 H34 N12 O2




CM 2

CRN 104-15-4
CMF C7 H8 O3 S




RN 658688-53-0 CAPLUS
CN Phenol, 2,2'-[[3-[(diethylamino)methyl]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)



RN 658688-54-1 CAPLUS
CN Phenol, 2,2'-[[3-[(diethylamino)methyl]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]-, mono(4-methylbenzenesulfonate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 658688-53-0
CMF C30 H33 N11 O2



CM 2


CRN 104-15-4

CMF C7 H8 O3 S



RN 658688-55-2 CAPLUS

CN Phenol, 2,2'-[[3-[(dimethylamino)methyl]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)




RN 658688-56-3 CAPLUS

CN Phenol, 2,2'-[[3-[(dimethylamino)methyl]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]-, mono(4-methylbenzenesulfonate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 658688-55-2


CMF C28 H29 N11 O2



CM 2


CRN 104-15-4

CMF C7 H8 O3 S



RN 658688-57-4 CAPLUS

CN Phenol, 2,2'-[[3-(4-morpholinylmethyl)phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 658688-58-5 CAPLUS

CN Phenol, 2,2'-[[3-(4-morpholinylmethyl)phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]-, mono(4-methylbenzenesulfonate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 658688-57-4


CMF C30 H31 N11 O3



CM 2


CRN 104-15-4

CMF C7 H8 O3 S




RN 658688-59-6 CAPLUS

CN Phenol, 2,2'-[[3-(ethyl(4-hydroxybutyl)amino)phenyl)methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl)imino)methyl]- (9CI) (CA INDEX NAME)




RN 658688-60-9 CAPLUS

CN Propanamide, 2-(acetyloxy)-N-[3-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl)imino)methyl]phenyl)methyl]phenyl]-2-methyl- (CA INDEX NAME)




RN 658688-64-3 CAPLUS

CN Ethanesulfonamide, N-[3-bis[2-hydroxy-5-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]phenyl]methyl]phenyl]-2,2,2-trifluoro-N-[(2,2,2-trifluoroethyl)sulfonyl]- (CA INDEX NAME)




RN 658688-65-4 CAPLUS

CN Propanamide, N-[3-bis[2-hydroxy-5-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]phenyl]methyl]phenyl]-2-hydroxy-2-methyl- (CA INDEX NAME)




RN 658688-66-5 CAPLUS

CN 1-Propanesulfonamide, N-[3-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]phenyl]methyl]phenyl]-N-(propylsulfonyl)- (CA INDEX NAME)




RN 658688-67-6 CAPLUS

CN 1-Propanesulfonamide, N-[3-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]phenyl]methyl]phenyl]-3-chloro-N-[(3-chloropropyl)sulfonyl]- (CA INDEX NAME)




RN 658688-68-7 CAPLUS

CN Acetamide, 2-(acetyloxy)-N-[3-bis[2-hydroxy-5-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]phenyl]methyl]phenyl]- (CA INDEX NAME)




RN 658688-69-8 CAPLUS

CN Methanesulfonamide, N-[3-bis[2-hydroxy-5-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]phenyl]methyl]phenyl]-N-(methylsulfonyl)- (CA INDEX NAME)




RN 658688-70-1 CAPLUS

CN Phenol, 2,2'-[[3-[(1,1-dioxido-2-isothiazolidinyl)phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 658688-71-2 CAPLUS

CN Acetamide, N-[3-{bis[2-hydroxy-5-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]phenyl]methyl]phenyl]-2-hydroxy- (CA INDEX NAME)




RN 658688-72-3 CAPLUS

CN Phenol, 2,2'-[[3-[ethyl(3-hydroxypropyl)amino]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (9CI) (CA INDEX NAME)




RN 658688-76-7 CAPLUS

CN Phenol, 2,2'-[[3-[[4-(acetyloxy)butyl]ethylamino]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (9CI) (CA INDEX NAME)




RN 658688-77-8 CAPLUS

CN Phenol, 2,2'-[[3-[[4-(2-hydroxyethyl)methylamino]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (9CI) (CA INDEX NAME)




RN 658688-78-9 CAPLUS

CN Phenol, 2,2'-[[3-[[4-(4-hydroxybutyl)methylamino]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (9CI) (CA INDEX NAME)




RN 658688-79-0 CAPLUS

CN Phenol, 2,2'-[[3-[(2-hydroxyethyl)propylamino]phenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (9CI) (CA INDEX NAME)




RN 658688-80-3 CAPLUS

CN Phenol, 2,2'-[[3-[(4-hydroxybutyl)propylamino]phenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (9CI) (CA INDEX NAME)




RN 658688-81-4 CAPLUS

CN Phenol, 2,2'-[[3-[(ethyl(6-hydroxyhexyl)amino)phenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (9CI) (CA INDEX NAME)




RN 658688-82-5 CAPLUS

CN Phenol, 2,2'-[[3-[ethyl(5-hydroxypentyl)amino]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (9CI) (CA INDEX NAME)




RN 658688-83-6 CAPLUS

CN Benzenesulfonamide, 4-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]phenyl]methyl]-N,N-bis(2-methoxyethyl)- (CA INDEX NAME)




RN 658688-84-7 CAPLUS

CN Benzenethanol, 4-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]phenyl]methyl]- (CA INDEX NAME)




RN 658688-85-8 CAPLUS

CN Morphinol, 4-[[4-[bis[2-hydroxy-5-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]phenyl]methyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 658688-86-9 CAPLUS


CN Phenol, 2,2'-[[4-(4-morpholinyl)phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)



RN 658688-87-0 CAPLUS
 CN Benzeneethanol, 4-[bis[2-hydroxy-5-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]phenyl]methyl]-, α -acetate (9CI) (CA INDEX NAME)



RN 658688-88-1 CAPLUS
 CN Phenol, 2,2'-[4-[(1-piperidinyl)phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)



L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 2003:742431 CAPLUS
 DOCUMENT NUMBER: 140:192261
 TITLE: Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro
 AUTHOR(S): Wyde, Philip R.; Chetty, Srikrishna N.; Jewell, Alan M.; Boivin, Guy; Piedra, Pedro A.
 CORPORATE SOURCE: Departments of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, 77030, USA
 SOURCE: Antiviral Research (2003), 60(1), 51-59
 CODEN: ARSRDR; ISSN: 0166-3542
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Human metapneumovirus (hMPV) is a newly recognized pathogen that like its

better-known relative, human respiratory syncytial virus (hRSV), appears to be ubiquitous and an important cause of respiratory disease in diverse subpopulations. No antivirals or vaccines are currently approved for the treatment or prevention of hMPV infections. However, ribavirin is licensed to treat serious hRSV-induced infections in children and immune globulin designed for i.v. administration (IVIG) and palivizumab (Synagis), a humanized monoclonal antibody preparation, have been utilized as alternatives to vaccines for preventing or reducing the severity of infections caused by this virus. Because both ribavirin and IVIG have broad viral specificities, studies were performed to compare the ability of these two agents to inhibit the replication of hRSV and hMPV in tissue culture-based assays. Two exptl. chemotherapeutic agents (i.e. VP14637 and JNJ2408068) and different antibody preps. were included in this testing for comparison. Ribavirin and the IVIG utilized were found to have equivalent antiviral activity against hMPV and hRSV. In contrast, except for antisera specifically raised against hMPV, all of the other materials tested had marked activity only against hRSV.


IT 235106-62-4, VP14637

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(inhibition of human metapneumovirus vs. respiratory syncytial virus by ribavirin and immune serum globulin in vitro)

RN 235106-62-4 CAPLUS

CN Phenol, 2,2'-[(4-hydroxyphenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2008 ACS ON STN

ACCESSION NUMBER: 2003:495542 CAPLUS

DOCUMENT NUMBER: 140:56326

TITLE: Structural characterization of respiratory syncytial virus fusion inhibitor escape mutants: homology model of the F protein and a syncytium formation assay

AUTHOR(S): Morton, Craig J.; Cameron, Rachel; Lawrence, Lynne J.; Lin, Bo; Lowe, Melinda; Luttick, Angela; Mason, Anthony; McKimm-Breschkin, Jenny; Parker, Michael W.; Ryan, Jane; Smout, Michael; Sullivan, Jayne; Tucker, Simon P.; Young, Paul R.

CORPORATE SOURCE: Biota Holdings Limited, Victoria, 3004, Australia

SOURCE: Virology (2003), 311(2), 275-288

CODEN: VIRLAX; ISSN: 0042-6822

PUBLISHER: Elsevier Science
DOCUMENT TYPE: Journal
LANGUAGE: English


AB Respiratory syncytial virus (RSV) is a ubiquitous human pathogen and the leading cause of lower respiratory tract infections in infants. Infection of cells and subsequent formation of syncytia occur through membrane fusion mediated by the RSV fusion protein (RSV-F). A novel in vitro assay of recombinant RSV-F function has been devised and used to characterize a number of escape mutants for three known inhibitors of RSV-F that have been isolated. Homol. modeling of the RSV-F structure has been carried out on the basis of a chimera derived from the crystal structures of the RSV-F core and a fragment from the orthologous fusion protein from Newcastle disease virus (NDV). The structure correlates well with the appearance of RSV-F in electron micrographs, and the residues identified as contributing to specific binding sites for several monoclonal antibodies are arranged in appropriate solvent-accessible clusters. The positions of the characterized resistance mutants in the model structure identify two promising regions for the design of fusion inhibitors.

IT 235106-62-4, VP14637

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(homol. model of F protein of respiratory syncytial virus fusion inhibitor escape mutants and a syncytium formation assay)

RN 235106-62-4 CAPLUS

CN Phenol, 2,2'-[(4-hydroxyphenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:318769 CAPLUS

DOCUMENT NUMBER: 139:173233

TITLE: Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein

AUTHOR(S): Douglas, Janet L.; Panis, Marites L.; Ho, Edmund; Lin, Kuei-Ying; Krawczyk, Steve H.; Grant, Deborah M.; Cai, Ruby; Swaminathan, Swami; Cihlar, Tomas

CORPORATE SOURCE: Gilead, Foster City, CA, 94404, USA


SOURCE: Journal of Virology (2003), 77(9), 5054-5064

CODEN: JOVIAM; ISSN: 0022-538X

PUBLISHER: American Society for Microbiology

DOCUMENT TYPE: Journal
 LANGUAGE: English


- AB Human respiratory syncytial virus (RSV) is a major cause of respiratory tract infections worldwide. Several novel small-mol. inhibitors of RSV have been identified, but they are still in preclin. or early clin. evaluation. One such inhibitor is a recently discovered triphenol-based mol., VP-14637 (ViroPharma). Initial expts. suggested that VP-14637 acted early and might be an RSV fusion inhibitor. Here we present studies demonstrating that VP-14637 does not block RSV adsorption but inhibits RSV-induced cell-cell fusion and binds specifically to RSV-infected cells with an affinity corresponding to its inhibitory potency. VP-14637 is capable of specifically interacting with the RSV fusion protein expressed by a T7 vaccinia virus system. RSV variants resistant to VP-14637 were selected; they had mutations localized to two distinct regions of the RSV F protein, heptad repeat 2 (HR2) and the intervening domain between heptad repeat 1 (HR1) and HR2. No mutations arose in HR1, suggesting a mechanism other than direct disruption of the heptad repeat interaction. The F proteins containing the resistance mutations exhibited greatly reduced binding of VP-14637. Despite segregating with the membrane fraction following incubation with intact RSV-infected cells, the compound did not bind to membranes isolated from RSV-infected cells. In addition, binding of VP-14637 was substantially compromised at temps. of ≤ 22 . Therefore, we propose that VP-14637 inhibits RSV through a novel mechanism involving an interaction between the compound and a transient conformation of the RSV F protein.
- IT 235106-62-4, VP 14637
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (inhibition of respiratory syncytial virus fusion by the small mol. VP-14637 via specific interactions with F protein)
- RN 235106-62-4 CAPLUS
- CN Phenol, 2,2'-[(4-hydroxyphenyl)methylene]bis[4-[[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:13479 CAPLUS
 DOCUMENT NUMBER: 135:70403
 TITLE: VP-14637 ViroPharma
 AUTHOR(S): McKimm-Breschkin, Jennifer
 CORPORATE SOURCE: Biomolecular Research Institute, Parkville, VIC 3052,

Australia
 SOURCE: Current Opinion in Investigational Drugs (PharmaPress Ltd.) (2000), 1(4), 425-427
 CODEN: COIDAZ
 PUBLISHER: PharmaPress Ltd.
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 AB A review, with 15 refs. VP-14637 is the lead compound in a series of low mol. weight viral replication inhibitors which are under preclin. investigation by ViroPharma for the potential treatment of RSV infection. Phase 1 trials designed to evaluate the safety and pharmacokinetic profile of VP-14637 in healthy human volunteers have begun. VP-14637 is most active against pneumoviruses and the available data suggest that it is an inhibitor of RSV viral fusion activity.
 IT 235106-62-4, VP 14637
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (VP-14637 for treatment of respiratory syncytial virus infection in humans)
 RN 235106-62-4 CAPLUS
 CN Phenol, 2,2'-[4-(4-hydroxyphenyl)methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)




REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1999:495171 CAPLUS
 DOCUMENT NUMBER: 131:144606
 TITLE: Preparation of heterocyclyl-substituted methylidynetrisphenol derivatives and related compounds for treating or preventing pneumovirus infection and associated diseases
 INVENTOR(S): Nitz, Theodore J.; Pevear, Daniel C.
 PATENT ASSIGNEE(S): Viropharma Incorporated, USA
 SOURCE: PCT Int. Appl., 45 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|-------------|
| WO 9938508 | A1 | 19990805 | WO 1999-US1985 | 19990129 |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KR, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW | | | | |
| RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2319465 | A1 | 19990805 | CA 1999-2319465 | 19990129 |
| EP 1051169 | A1 | 20001115 | EP 1999-905546 | 19990129 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| BR 9908522 | A | 20011002 | BR 1999-8522 | 19990129 |
| JP 2002501894 | T | 20020122 | JP 2000-529241 | 19990129 |
| NZ 505894 | A | 20021220 | NZ 1999-505894 | 19990129 |
| AU 759772 | B2 | 20030501 | AU 1999-25685 | 19990129 |
| US 6495580 | B1 | 20021217 | US 1999-254690 | 19991018 |
| MX 2000PA07394 | A | 20030801 | MX 2000-PA7394 | 20000728 |
| US 2003092685 | A1 | 20030515 | US 2002-280528 | 20021025 |
| IN 2003DE00960 | A | 20050225 | IN 2003-DE960 | 20030804 |
| PRIORITY APPLN. INFO.: | | | US 1998-73038P | P 19980129 |
| | | | US 1998-73078P | P 19980130 |
| | | | WO 1999-US1985 | W 19990129 |
| | | | IN 1999-DE959 | A3 19990710 |
| | | | US 1999-254690 | A3 19991018 |

OTHER SOURCE(S): MARPAT 131:144606
GI



AB The title compds. I [Het = 5-7 membered heterocyclic ring; R1 = H, halo, perfluoroalkyl, amino, etc.; R2 = H, OH, thio, alkoxy, etc.; X = N:CH, CH:N, N:N, etc.; Z = H, CHO, OH, X(Het)], useful for treatment of infections caused by viruses of the Pneumovirinae subfamily of Paramyxoviridae and diseases associated with such infections, were prepared E.g., 5,5'-bis[1-((5-amino-1H-tetrazolyl)imino)methyl]-2,2',4'-methylidynetrisphenol was prepared The antiviral activity of I toward pneumovirus was determined The cytotoxicity of I toward healthy cells was also determined

IT 235106-62-4P 235106-75-9P 235106-77-1P
235106-79-3P 235106-80-6P 235106-81-7P
235106-83-9P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclyl-substituted methylidynetrisphenol derivs. and related compds. for treating or preventing pneumovirus infection)


RN 235106-62-4 CAPLUS

CN Phenol, 2,2'-[4-(4-hydroxyphenyl)methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)




RN 235106-75-9 CAPLUS

CN Phenol, 2,2'-[[4-[2-(diethylamino)ethoxy]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)




RN 235106-77-1 CAPLUS

CN Acetic acid, [4-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]phenyl]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 235106-79-3 CAPLUS

CN Phenol, 2,2'-[[4-(4-pyridinyl)phenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 235106-80-6 CAPLUS

CN Phenol, 2,2'-[[4-(4-nitrophenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 235106-81-7 CAPLUS

CN Phenol, 2,2'-[[4-(4-aminophenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (9CI) (CA INDEX NAME)



RN 235106-83-9 CAPLUS
 CN Phenol, 2,2'-(phenylmethylene)bis[4-[[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log h

COST IN U.S. DOLLARS

| | |
|------------|---------|
| SINCE FILE | TOTAL |
| ENTRY | SESSION |
| 54.98 | 233.55 |

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

| | |
|------------|---------|
| SINCE FILE | TOTAL |
| ENTRY | SESSION |
| -8.00 | -8.00 |

CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 08:52:18 ON 19 FEB 2008